Alzamend Neuro Stock Return On Asset
| ALZN Stock | USD 1.26 0.06 5.00% |
Alzamend Neuro fundamentals help investors to digest information that contributes to Alzamend Neuro's financial success or failures. It also enables traders to predict the movement of Alzamend Stock. The fundamental analysis module provides a way to measure Alzamend Neuro's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alzamend Neuro stock.
As of the 5th of January 2025, Return On Assets is likely to grow to -17.21. Alzamend | Return On Asset |
Alzamend Neuro Company Return On Asset Analysis
Alzamend Neuro's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Alzamend Neuro Return On Asset | -2.14 |
Most of Alzamend Neuro's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alzamend Neuro is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alzamend Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Alzamend Neuro is extremely important. It helps to project a fair market value of Alzamend Stock properly, considering its historical fundamentals such as Return On Asset. Since Alzamend Neuro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alzamend Neuro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alzamend Neuro's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Alzamend Net Tangible Assets
Net Tangible Assets |
|
Based on the latest financial disclosure, Alzamend Neuro has a Return On Asset of -2.1447. This is 75.49% lower than that of the Biotechnology sector and 90.91% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Alzamend Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alzamend Neuro's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alzamend Neuro could also be used in its relative valuation, which is a method of valuing Alzamend Neuro by comparing valuation metrics of similar companies.Alzamend Neuro is currently under evaluation in return on asset category among its peers.
Alzamend Fundamentals
| Return On Equity | -44.08 | ||||
| Return On Asset | -2.14 | ||||
| Current Valuation | 6.77 M | ||||
| Shares Outstanding | 5.43 M | ||||
| Shares Owned By Insiders | 4.55 % | ||||
| Shares Owned By Institutions | 0.94 % | ||||
| Number Of Shares Shorted | 62.94 K | ||||
| Price To Book | 1.82 X | ||||
| EBITDA | (9.89 M) | ||||
| Net Income | (9.95 M) | ||||
| Cash And Equivalents | 11.53 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 300.71 K | ||||
| Current Ratio | 11.78 X | ||||
| Book Value Per Share | (3.77) X | ||||
| Cash Flow From Operations | (8.27 M) | ||||
| Short Ratio | 1.03 X | ||||
| Earnings Per Share | (138.31) X | ||||
| Target Price | 32.0 | ||||
| Beta | -0.038 | ||||
| Market Capitalization | 6.85 M | ||||
| Total Asset | 631.59 K | ||||
| Retained Earnings | (54.02 M) | ||||
| Working Capital | (2.77 M) | ||||
| Net Asset | 631.59 K |
About Alzamend Neuro Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alzamend Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alzamend Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alzamend Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock: Check out Alzamend Neuro Piotroski F Score and Alzamend Neuro Altman Z Score analysis. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.